M&A Deal Summary |
|
|---|---|
| Date | 2019-03-12 |
| Target | Novartis AG - Farydak |
| Sector | Life Science |
| Buyer(s) | Secura Bio |
| Sellers(s) | Novartis |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2019 |
| Sector | Life Science |
Secura Bio is a commercial-stage biopharmaceutical company that offers oncology therapies for physicians and their patients. Secura Bio was founded in 2019 and is based in Berkeley Heights, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Divestiture M&A Deals | 1 of 2 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-30 |
Verastem - COPIKTRA
Needham, Massachusetts, United States Verastem's COPIKTRA (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first FDA-approved dual inhibitor of PI3K-delta and PI3K-gamma. |
Buy | $381M |
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 104,323 |
| Revenue | 51.8B USD (2024) |
Novartis is a healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 8 |
| Sector: Life Science M&A | 4 of 4 |
| Type: Divestiture M&A Deals | 4 of 7 |
| Country: Switzerland M&A | 3 of 6 |
| Year: 2019 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-10-18 |
Endocyte
West Lafayette, Indiana, United States Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company’s agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. |
Buy | $2.1B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-04-01 |
IFM Tre
Boston, Massachusetts, United States IFM Tre is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system through the NLRP3 pathway, which is believed to underlie a variety of serious diseases. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. |
Buy | $1.6B |
